Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Iberdomide
Drug: Lenalidomide

First Posted Date: 2023-04-24

Last Posted Date: 2025-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1216

Registration Number: NCT05827016

Locations: 🇹🇷
Local Institution - 0068, Istanbul, Turkey
🇺🇸
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

and more 274 locations

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent Grade 3b Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Drug: Ifosfamide
Drug: Lenalidomide
Procedure: Positron Emission Tomography
Biological: Tafasitamab

First Posted Date: 2023-04-20

Last Posted Date: 2024-11-15

Lead Sponsor: David Bond, MD

Target Recruit Count: 37

Registration Number: NCT05821088

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2

Withdrawn

Conditions: Multiple Myeloma
Myeloma-Associated Amyloidosis

Interventions: Drug: Selinexor
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2023-04-20

Last Posted Date: 2024-07-10

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT05820763

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy with Either Intravenous or Subcutaneous Isatuximab in Patients with Newly Diagnosed Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2023-04-07

Last Posted Date: 2025-03-07

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 514

Registration Number: NCT05804032

Locations: 🇩🇪
University of Würzburg, Med. Klinik und Poliklinik II, Würzburg, Germany
🇩🇪
Universitätsklinikum Magdeburg, Magdeburg, Germany
🇩🇪
Universitätsklinikum Münster, 1. Medizinische Klinik A, Münster, Germany

and more 88 locations

The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Colchicine
Drug: Lenalidomide

First Posted Date: 2023-04-07

Last Posted Date: 2023-04-07

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 30

Registration Number: NCT05802992

Locations: 🇨🇳
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Not Applicable

Conditions: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Zanubrutinib
Drug: Lenalidomide
Drug: CD19/CD22 CAR-T
Drug: Azacitidine For Injection
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2023-04-04

Last Posted Date: 2023-04-04

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 20

Registration Number: NCT05797948

Locations: 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 2

Terminated

Conditions: Mantle Cell Lymphoma
MCL

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2023-03-28

Last Posted Date: 2025-04-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT05788289

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States

and more 4 locations